DEVELOPMENT OF A NALTREXONE MICROCAPSULE INJECTION

描述：（改编自申请人摘要）。BIOTEK，INC 建议开发一种临床上有用的缓释纳洛酮， 用于减少最近戒断者再成瘾的微胶囊 施虐者纳洛酮是一种阿片拮抗剂， 阻断了麻醉剂的强化机制微胶囊 目标是含有超过50%的药物， 5 mg/天，持续1个月。申请人先前已经开发了一种 可注射的纳洛酮微囊产生阿片样物质拮抗作用， 30天或更长时间。PI计划复制（并改进和 优化，如有必要）原型配方，进行必要的 需要提交IND的研究。

DESCRIPTION: (Adapted from the Applicant's Abstract). BIOTEK, INC proposes to develop a clinically useful sustained release naltrexone microcapsules for reducing re-addiction among recently withdrawn abusers. Naltrexone is an opiate antagonist which physiologically blocks the narcotic reinforcement mechanism. The microcapsules are targeted to contain more than 50 percent drug and deliver approximately 5 mg/day for 1 month. The applicant has previously developed an injectable naltrexone microcapsules which produced opioid antagonism for 30 days or more in monkeys. The PI plans to reproduce (and improve and optimize, if necessary) the prototype formulation, conduct the necessary studies needed to submit an IND.